(Q37600395)

21 August 2017

1 reference

title

Health economic issues in the treatment of drug-resistant serious Gram-positive infections (English)

1 reference

21 August 2017

gram-positive bacteria

0 references

author name string

Dilip Nathwani

series ordinal

1

1 reference

21 August 2017

1 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

59 Suppl 1

1 reference

21 August 2017

S40-50

1 reference

Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Meticillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Epidemiology of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Antimicrobial resistance in Europe and its potential impact on empirical therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Hospital-acquired neonatal infections in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Staphylococcus aureus bacteremia, Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Methicillin-resistant-Staphylococcus aureus hospitalizations, United States

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Methicillin-resistant Staphylococcus aureus disease in three communities

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Infection control and changing health-care delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

What is the most effective way to reduce incidence of amputation in the diabetic foot?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

The challenge of changing healthcare systems

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Hospital provision, activity, and productivity in England since the 1980s.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Intravenous antimicrobial therapy in the community: underused, inadequately resourced, or irrelevant to health care in Britain?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Healthcare reform in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Impact of glycopeptide therapy after hospital discharge on inpatient costs: a comparison of teicoplanin and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Five common fallacies in estimating the economic gains of early discharge

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Factors influencing physicians' decision to discharge hospitalized patients infected with methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

In pursuit of quality: the National Institute for Clinical Excellence

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Current trends in the use of pharmacoeconomics and outcomes research in europe

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Economic impact of antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Systematic review of economic analyses of health care-associated infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Evaluating the BMJ guidelines for economic submissions: prospective audit of economic submissions to BMJ and The Lancet

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Being economical with the truth: how to make your idea appear cost effective

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Economic Notes: opportunity cost

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Has health economics lost its way?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Economic notes. Discounting

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Pharmacoeconomics of linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Cost and morbidity of MRSA in head and neck cancer patients: what are the consequences?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Some guidelines on the use of cost effectiveness league tables

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Hospital response to DRG refinements: the impact of multiple reimbursement incentives on inpatient length of stay

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Health-economic consequences of diabetic foot lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Diabetic foot ulcers in a multidisciplinary setting. An economic analysis of primary healing and healing with amputation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Methicillin-resistant Staphylococcus aureus: A public health issue with economic consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Clinical and economic consequences of ventilator-associated pneumonia: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Economics and preventing hospital-acquired infection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Reference group choice and antibiotic resistance outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Health and economic outcomes of vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

The economic impact of Staphylococcus aureus infection in New York City hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960007-4

7 January 2021

10.1016/S0163-4453(09)60007-4

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19766889